Take part in our clinical research!
Multiple hospitals are investigating our Artimis® meniscus prosthesis. We are always happy to meet new patients willing to experience our innovation.
Participate in our next study!
We welcome your input as clinicians. ATRO Medical will internationally expand its clinical research. We look forward to collaborate with you.
Are you suffering from knee pain after a meniscectomy? ATRO Medical’s artificial meniscus Artimis® replaces your meniscus. This means you will return to your daily activities, with heavy sports excluded, while reducing chronic pains: a flexible yet strong solution to your knee problems. We are in the clinical phase and investigate the effectiveness of our prostheses.
Learn more about ATRO Medical at following conferences:
We’ll be pitching our artificial meniscus at the HealthTech Investor Summit in Utrecht.
Founder Tony van Tienen will present Artimis' clinical data
ATRO Medical
Research on the new artificial meniscus
A study on the effectiveness of our prosthesis is currently underway. Three hospitals are conducting it:
• St. Maartenskliniek in Nijmegen
• Radboudumc
• MUMC+ in Maastricht
ATRO Medical
ATRO Medical was founded by Dr. Tony van Tienen in 2016. When Van Tienen was working as an orthopedic knee surgeon, he encountered many patients who were suffering severe knee pain after a meniscus removal but were too young for a knee replacement. And their knee cartilage was actually too good to be replaced by metal and plastic. There was no fitting solution available, and as a result, these people experienced long episodes of pain.
ATRO Medical started as a spin-off from Radboudumc and DSM. After many years of academic research, these two parties decided assist van Tienen in launching a company to let the dream of an artificial meniscus come true.
Collaborate?
ATRO Medical is a team of specialists that work hard towards a common goal: realizing a lasting, innovative, and unique solution for patients with chronic knee pains. This requires knowledge, patience, and perseverance. With step-by-step improvements, we move closer to that goal.
Our efforts have been noticed internationally. ATRO Medical has received an important acknowledgment by the American government’s FDA, the ‘FDA breakthrough device designation' In addition, the European Innovation Council (EIC) has rewarded ATRO Medical with the EIC Accelerator grant, and The Dutch Arthritis Society has become an official partner.
Join forces?
ATRO Medical is always looking for partnerships. Are you a doctor, physiotherapist, radiologist, or insurer? Do you work for an orthopedic company or want to join forces another way? Please feel welcome to contact us.
Read all about the latest scientific developments.
ATRO Medical, the Dutch clinical-stage orthopedic company developing a novel artificial meniscus implant for patients suffering from post-meniscectomy pain, today announces the successful closing of a €3 million financing round. The financing round is primarily composed of equity investments, complemented by non-dilutive funding. It brings together MedTech investors from the Netherlands, Switzerland, and the United Arab Emirates such as 819 Capital, Thuja Capital, Bolwork International Investment and industry leaders DSM-Firmenich Ventures and Samaplast.
As the first company worldwide, ATRO Medical has started a clinical trial on a lateral artificial meniscus. For the first time ever, an absent meniscus in the outer knee compartment is replaced by an artificial meniscus, the Artimis® Meniscus Prosthesis. The first patient in this study has been treated at the Radboud University Medical Center in Nijmegen.
This clinical study is initiated in October 2021 to enroll 14 patients at select medical centers in the Netherlands. The study is full and can no longer accept new participants. The clinical study is approved by the Dutch government (Dutch Health and Youth Care Inspectorate) and Medical Research Ethics Committee.